AxoGen (NASDAQ: AXGN) is one of 46 public companies in the “Electromedical equipment” industry, but how does it contrast to its rivals? We will compare AxoGen to similar businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, earnings and risk.
Earnings & Valuation
This table compares AxoGen and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|AxoGen||$60.43 million||-$10.44 million||-128.06|
|AxoGen Competitors||$1.10 billion||$121.87 million||-38.49|
This is a summary of current recommendations and price targets for AxoGen and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AxoGen currently has a consensus target price of $33.14, suggesting a potential downside of 16.52%. As a group, “Electromedical equipment” companies have a potential upside of 18.66%. Given AxoGen’s rivals higher possible upside, analysts plainly believe AxoGen has less favorable growth aspects than its rivals.
Institutional & Insider Ownership
67.8% of AxoGen shares are held by institutional investors. Comparatively, 40.7% of shares of all “Electromedical equipment” companies are held by institutional investors. 7.9% of AxoGen shares are held by company insiders. Comparatively, 20.2% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares AxoGen and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
AxoGen has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, AxoGen’s rivals have a beta of 1.57, meaning that their average stock price is 57% more volatile than the S&P 500.
AxoGen rivals beat AxoGen on 9 of the 13 factors compared.
AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.